

EY Pharma Agentic AI – Innovation Brief for Tiotropium

Region: India | Time Horizon: 5 years | User Query: Find innovation opportunities for tiotropium in India over 5 years

Executive Summary

Synthesizing findings for Tiotropium in India over 5 years. Strategic Signals

- Whitespace: High-value but under-explored market: estimated market size ~USD 155m with only 2 active/recruiting trials in the mock pipeline.
- Opportunity: Key patent US1234567A (composition) expires in 2025, suggesting a window for biosimilars or differentiated formulations. Agent Findings
- IQVIA Insights Agent: Market for Tiotropium in India grew from USD 120m in 2021 to 155m in 2024, with a CAGR of ~7.9%. Competition is moderate with 4 active players.
- EXIM Trade Agent: In India, latest mock EXIM data shows imports of 620 kg and exports of 70 kg for Tiotropium, at an average unit price of USD 115. Key source countries: China|Germany.
- Patent Landscape Agent: Mock patent landscape shows 3 filings for Tiotropium. Earliest expiry is US1234567A (composition) expiring in 2025 with FTO risk rated 'high'.
- Clinical Trials Agent: Mock clinical pipeline in India shows 2 active or recruiting trials for Tiotropium, across phases: {'Phase 3': 1, 'Phase 2': 1}.
- Internal Insights Agent: Mock internal strategy decks highlight adherence issues and access gaps for LAMA inhalers, suggesting opportunity in device innovation and patient education programs.
- Web Intelligence Agent: Mock web and guideline snippets indicate persistent symptoms and poor inhaler technique in COPD patients on tiotropium, and underutilisation in severe asthma despite evidence of benefit.

IQVIA Insights Agent

Market for Tiotropium in India grew from USD 120m in 2021 to 155m in 2024, with a CAGR of ~7.9%. Competition is moderate with 4 active players.

EXIM Trade Agent

In India, latest mock EXIM data shows imports of 620 kg and exports of 70 kg for Tiotropium, at an average unit price of USD 115. Key source countries: China|Germany.

Patent Landscape Agent

Mock patent landscape shows 3 filings for Tiotropium. Earliest expiry is US1234567A (composition) expiring in 2025 with FTO risk rated 'high'.

Clinical Trials Agent

Mock clinical pipeline in India shows 2 active or recruiting trials for Tiotropium, across phases: {'Phase 3': 1, 'Phase 2': 1}.

Internal Insights Agent

Mock internal strategy decks highlight adherence issues and access gaps for LAMA inhalers, suggesting opportunity in device innovation and patient education programs.

Web Intelligence Agent

Mock web and guideline snippets indicate persistent symptoms and poor inhaler technique in COPD patients on tiotropium, and underutilisation in severe asthma despite evidence of benefit.